{
  "meta": {
    "title": "Ini_Cet_Nov_2023",
    "url": "https://brainandscalpel.vercel.app/ini-cet-nov-2023-7802722f.html",
    "scrapedAt": "2025-11-30T07:35:19.640Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Remove placenta and reposition uterus</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Reposition uterus inside without removing placenta</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Shift to OT and insert the uterus back</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Separate placenta first</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient with outside delivery came to emergency room with something coming out. PV with placenta attached to mass. Patient is semiconscious, her pulse feeble and hypovolemia. Periphery calm and cold. She was diagnosed with uterine inversion with placenta attached. What is the management of this patient?</span></p>",
      "unique_key": "DT1322043",
      "question_audio": null,
      "question_video": null,
      "map_id": 1322043,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>If the placenta is still attached in an inverted uterus, then <strong>attempts are made to reposition uterus with</strong> <strong>placenta in situ.</strong></li>\r\n<li><strong>Trying to remove placenta before repositioning the uterus leads to neurogenic shock.</strong></li>\r\n<li><strong>Oxytocin should not be started</strong></li>\r\n<li><strong>IV administration of tocolytic drugs</strong> like terbutaline, magnesium sulfate or nitroglycerine for uterine relaxation and repositioning.</li>\r\n<li><strong>If these fails inhalational halogen given</strong></li>\r\n<li><strong>After replacing uterus, placenta removed.</strong></li>\r\n<li><strong>Then Oxytocin can be started</strong></li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGMCQ/202504071f7cfa54-017c-45d5-941c-810722dcf3df.jpg\">",
      "correct_choice_id": 2,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Start Oxytocin</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Start Oxytocin</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Rupture membranes and confirm cord prolapse</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Wait and watch</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A G3P2L2 patient came in labour. On her P/V examination, cervix 70% effaced, 3 cm dilated, station-1, anterior cervix, bag of worms felt. What is the next best step?</span></p>",
      "unique_key": "DT1322044",
      "question_audio": null,
      "question_video": null,
      "map_id": 1322044,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>\"Bag of worms felt\" means cord presentation in an intact amniotic membrane and requires immediate LSCS</strong></p>\r\n<p><strong>Option A: Starting Oxytocin may cause cord prolapse due to increased contraction</strong></p>\r\n<p><strong>Option C: Rupturing the membranes will lead to cord prolapse and cause fetal distress</strong></p>\r\n<p><strong>Option D: Wait and watch is not feasible</strong></p>\r\n<p><strong>Hence by ruling out the other options we can come to the option of emergency LSCS.</strong></p>\r\n<p><strong>Management of cord prolapse:</strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGMCQ/20250407c4dd97dc-b9bb-49d2-a04a-2beb8530041e.jpg\">",
      "correct_choice_id": 13,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\"><p>Administer DMPA in the next cycle  </p></span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\"><p>Take DMPA with backup for 7 days  </p></span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\"><p>Take DMPA, and no backup needed </p></span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\"><p>Ask to do UPT before taking DMPA  </p></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\"><p>A 30-year-old nulligravida is on DMPA, and she comes 14 days past her due date for her next DMPA. What should be advised to her? </p></span></p>",
      "unique_key": "DT1322045",
      "question_audio": null,
      "question_video": null,
      "map_id": 1322045,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul><li>The administration of depot medroxyprogesterone acetate (DMPA) is done<strong> every 3 months (13 weeks).</strong> It does <strong>not require backup </strong>contraception if given within a grace period of <strong>up to 2 weeks earlier or 4 weeks later</strong> than the scheduled date. If the injection is delayed <strong>beyond this 4-week grace period, pregnancy should be excluded</strong> before the next dose. </li><li><strong>Dosage and route: </strong>150 mg IM every 90 days.  <strong> </strong> </li><li><strong>Mechanism of action:</strong> <ul><li>Inhibition of ovulation  </li><li>Makes cervical mucus thick and viscid, preventing sperm penetration </li><li>Prevents implantation by altering the endometrium  </li></ul></li><li><strong>Effects: </strong> <ul><li>DMPA does not affect lactation.  </li><li>DMPA reduces the risk of iron deficiency anaemia, sickle cell problems, and endometriosis. </li><li>There is a delayed return of fertility (6-12 months). </li></ul></li><li><strong>Side effects: </strong>Reduced bone mineral density, depression, weight gain, and headache. </li></ul><p><strong>Explanation of Other Options:</strong> </p><p><strong>Administer DMPA in the next cycle (Option A) </strong>is not a usually followed step. This is because, if the woman comes any time after 1 month of her dose date, she has to take a UPT, and if negative, she is given the next dose regardless of her next cycle.  </p><p><strong>Take DMPA with backup for 7 days (Option B) </strong>if the woman comes 1 month after the scheduled date of injection (4 months from the first dose). She must also be tested for pregnancy and, if negative, administer DMPA. This is not the given scenario.  </p><p><strong>Ask to do UPT before taking DMPA (Option D) </strong>if the patient has come after 1 month of the scheduled date of injection, which is not the scenario here.  </p><p> </p><p><br> </p><p> </p>",
      "correct_choice_id": 23,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">OCP intake</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Functional ovarian cyst</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">PCOS</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Nulliparity</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following has risk of progressing to borderline ovarian tumour?</span></p>",
      "unique_key": "DT1322046",
      "question_audio": null,
      "question_video": null,
      "map_id": 1322046,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>According to theory of incessant ovulation, more a woman ovulates more the chances of ovarian malignancy.</p>\r\n<p>Option A: Females taking OCPs ovulate less, hence less risk of ovarian malignancy</p>\r\n<p>Option C: Females with PCOS have more of anovulatory cycles and hence is protective</p>\r\n<p>Option D: Multiparity means lesser ovulation cycles and hence is protective whereas <strong>Nulliparity is a risk factor</strong></p>\r\n<p>Option B: Functional ovarian cysts are benign and hence do not have risk of conversion to malignancy.</p>\r\n<p><strong>Following are the risk factors of ovarian malignancy:</strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGMCQ/2025040729fb9f64-dd6d-4faa-8f7f-d733ea1d1691.jpg\">",
      "correct_choice_id": 34,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">E1 + E2</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">E6+ E7</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">L1</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">L2</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Antigen present in recombinant HPV vaccine:</span></p>",
      "unique_key": "DT1322047",
      "question_audio": null,
      "question_video": null,
      "map_id": 1322047,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>Antigen for HPV vaccine is <strong>L1 major capsid protein of HPV, </strong>produced by using recombinant DNA technology.</p>\r\n<p><strong>L1 protein self-assemble into noninfectious, nononcogenic units called virus like particles(VLP).</strong></p>\r\n<p><strong>Option B: E6 and E7 are oncogenes by which HPV causes cervical CA</strong></p>",
      "correct_choice_id": 43,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Long arm of Y chromosome </span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Short arm of Y chromosome </span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Long arm of X chromosome </span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Short arm of  X chromosome</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">SRY gene located at</span></p>",
      "unique_key": "DT1322048",
      "question_audio": null,
      "question_video": null,
      "map_id": 1322048,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>Male sexual differentiation is an active process requiring the presence of the <strong>SRY GENE which is located on Short aRm of Y chromosome.</strong></p>\r\n<p>Clinically, <u>gender is not apparent until about 12 week of embryonic life </u>and depends on the elaboration of testes determining factor and subsequently, androgen by male gonads.</p>",
      "correct_choice_id": 52,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Point mutation</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Deletion of gene</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Translocation</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Inversion</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In 46 XX female on doing amniocentesis complete gonadal dysgenesis was noted. Complete gonadal dysgenesis is caused by what in the SRY gene?</span></p>",
      "unique_key": "DT1322049",
      "question_audio": null,
      "question_video": null,
      "map_id": 1322049,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>Complete gonadal dysgenesis is also known as <strong>SWYER SYNDROME. </strong></p>\r\n<p><strong>In this approximately 15-20% of patients, the disorder results from an inactivating point mutation in SRY gene, but in most cases cause is not known.</strong></p>\r\n<p>(Deletion in SRY gene's DNA binding region 2 is present in 10-20 % of women)</p>",
      "correct_choice_id": 61,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Chances of bowel injury due to PAS</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Chances of bladder injury due to PAS</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Chances of hysterectomy due to PAS</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Chances of blood transfusion</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 39-year-old female with G6P3L3A2 came to OPD having full term pregnancy with previous 3 LSCS. She is diagnosed case of PAS. What will not be mentioned in the consent?</span></p>",
      "unique_key": "DT1322050",
      "question_audio": null,
      "question_video": null,
      "map_id": 1322050,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>Placenta Accreta Spectrum(PAS) disorder has disastrous outcome for both mother and fetus. Chances of bowel injury are very rare</p>\r\n<p>It includes:</p>\r\n<ul>\r\n<li>Placenta <strong>A</strong>ccreta: Placenta <strong>A</strong>dherent to myometrium</li>\r\n<li>Placenta <strong>I</strong>ncreta: Placenta <strong>I</strong>nvading myometrium</li>\r\n<li>Placenta <strong>P</strong>ercreta: Placenta <strong>P</strong>erforating through myometrium</li>\r\n</ul>\r\n<p>Cause: Due to absence of Nitabuch's layer</p>\r\n<p>It should be terminated at tertiary care center.</p>\r\n<p><strong>Complication of surgery for PAS includes:</strong></p>\r\n<ul>\r\n<li>Long operative time</li>\r\n<li><strong>Blood and blood product transfusion(Option D)</strong></li>\r\n<li><strong>Surgical complications like bladder injury(Option B)</strong></li>\r\n<li>ICU admission</li>\r\n<li>Increased length of stay</li>\r\n</ul>\r\n<p><strong>Management: Caesarean Hysterectomy(Option C)</strong></p>",
      "correct_choice_id": 73,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">OCP</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Lifestyle modification</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Inform about metabolic syndrome risk</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">OCP+Antiandrogen</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 25 year old girl with BMI 29 presented to OPD with complains of irregular cycles. She has hirsutism with a score of 6 and testosterone levels are high. Her mother is diabetic and is on medication. What should not be advised?</span></p>",
      "unique_key": "DT1322051",
      "question_audio": null,
      "question_video": null,
      "map_id": 1322051,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>Irregular cycles with hyperandrogenic features in a young female points towards PCOS. Antiandrogens do not constitute the first line of management in a case of PCOS.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGMCQ/202504071893df9d-8327-4e89-8bca-6b2498831e96.jpg\">\r\n\r\n<p><strong>PCOS management:</strong></p>\r\n<ul>\r\n<li><strong>Lifestyle modification is first line approach for PCOS management. It includes weight loss, healthy diet, exercise and counselling about metabolic syndrome(Option B,C)</strong></li>\r\n<li><strong>Menstrual irregularity:</strong> it is <strong>treated with OCP(Option A)</strong></li>\r\n<li><strong>Hirsutism: </strong>It is treated with OCP and <strong>antiandrogenic drugs, only if the patient doesn&rsquo;t respond to OCPs</strong></li>\r\n<li><strong>Infertility: </strong>treated with ovulation induction along with metformin</li>\r\n</ul>",
      "correct_choice_id": 84,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Antihypertensives and Emergency LSCS</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Start antihypertensives and tocolytics</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Start antihypertensives and do ARM</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Observation</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 4th gravida patient of 30-week pregnancy came to LR with complaint of painful bleeding PV with reduced fetal movement. On examination, uterus is tonically contracted. Uterus has size of 34 weeks. FHR absent. BP-166/110 mmHg. She had wet undergarments but bleeding has stopped now. On P/V examination, cervix 6 cm dilated, 70% effaced. Next step?</span></p>",
      "unique_key": "DT1322052",
      "question_audio": null,
      "question_video": null,
      "map_id": 1322052,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>This seems to be a case of antepartum haemorrhage with hypertension and probable intrauterine fetal death. Most probably, a case of Abruptio placenta with preeclampsia. Management includes:</p>\r\n<ul>\r\n<li>Abruptio: Definitive management is by vaginal delivery using ARM followed by Oxytocin(Emergency LSCS in case of fetal distress)</li>\r\n<li>If the fetus has died, <strong>vaginal delivery</strong> <strong>preferred</strong>.</li>\r\n</ul>\r\n<p><strong>-&gt;Early amniotomy</strong> in the management of abruption is needed. It achieves better spiral artery compression to diminish implantation site bleeding and reduce thromboplastin infusion into the maternal vascular system.</p>\r\n<p><strong>-&gt;Membrane rupture may hasten delivery</strong>.</p>\r\n<p>-&gt;If rhythmic uterine contractions are not superimposed on baseline hypertonus, <strong>oxytocin is given in standard doses.</strong></p>\r\n<p>-&gt;No data indicate that oxytocin augments thromboplastin escape into the maternal circulation to worsen coagulopathy.</p>\r\n<p>Options A: Emergency LSCS is indicated in cases of fetal distress and in this case fetus is already dead.</p>\r\n<p>Option B: Tocolytics won't help here as we need to expedite the delivery of the dead fetus</p>\r\n<p>Option D: Observation won't suffice as mother can go into DIC if not managed immediately</p>",
      "correct_choice_id": 93,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Chemotherapy F/B debulking surgery</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Debulking surgery F/B chemotherapy</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Chemotherapy alone</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Staging laparotomy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 65-year-old woman with epithelial ovarian cancer undergoes CT scan. CT scan shows omental caking and peritoneal metastasis with ascites. What is the management?</span></p>",
      "unique_key": "DT1322053",
      "question_audio": null,
      "question_video": null,
      "map_id": 1322053,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>Peritoneal metastasis as given in the question depicts Stage 3b ovarian cancer.Check out the TNM staging of ovarian cancer:</p>\r\n<p>According to THIS FIGO staging,</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGMCQ/20250407f6b4143e-85a7-4dbf-8b5e-9150f74ebc6f.jpg\">\r\n<p><strong>STAGE 1 AND 2 IS EARLY OVARIAN CANCER AND STAGE 3 AND 4 IS ADVANCED OVARIAN CANCER.</strong></p>\r\n<p><strong>Management:</strong></p>\r\n<ul>\r\n<li><strong>Staging laparotomy f/b 6 cycles of chemotherapy(except in stage IA,IB where chemotherapy is skipped)</strong></li>\r\n<li><strong>In advanced stages(Omental caking, ascites, peritoneal metastasis), Neoadjuvant chemotherapy</strong><strong>&agrave;</strong><strong>Debulking surgery</strong><strong>&agrave;</strong><strong>Chemotherapy given</strong></li>\r\n</ul>",
      "correct_choice_id": 101,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Ovarian artery</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Uterine artery</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Arcuate artery</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Round ligament artery</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">If we ligate uterine artery for PPH, which of the following arteries will serve as an alternate source of vascularity to uterus to prevent uterine ischemia?</span></p>",
      "unique_key": "DT1322054",
      "question_audio": null,
      "question_video": null,
      "map_id": 1322054,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>Uterus is supplied by both Ovarian and uterine artery. <strong>The ovarian branch of uterine artery anastomoses with the ovarian artery to form an alternate source of supply for the uterus in case the uterine artery is ligated.</strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGMCQ/20250407d0fece0a-c433-4eb5-b8ab-5a345115c8a8.jpg\">\r\n<p><strong>Fig. Blood supply of uterus</strong></p>",
      "correct_choice_id": 111,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">INFLUENZA</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">HSV 2</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">CMV</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">CMV</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which viral infection contracted in pregnancy is not teratogenic?</span></p>",
      "unique_key": "DT1322055",
      "question_audio": null,
      "question_video": null,
      "map_id": 1322055,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>HSV2, CMV, RUBELLA are teratogenic.</strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGMCQ/20250407df571d99-0a97-4542-a54a-3d278c9bb391.jpg\">\r\n<p><strong>Herpes infection can be transmitted to fetus only during vaginal delivery from the genital lesions and hence LSCS is indicated in those cases. Herpes won't cause any teratogenicity in the fetus.</strong></p>",
      "correct_choice_id": 121,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased fluid retention</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Action of Aldosterone and estrogen</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Aldosterone and ADH</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">OPTION A+B</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What is the reason for increase in blood volume at term in pregnancy?</span></p>",
      "unique_key": "DT1322056",
      "question_audio": null,
      "question_video": null,
      "map_id": 1322056,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>Plasma volume appears to increase at term due to activation of Renin-Angiotensin-Aldosterone system(RAAS) activation.</p>\r\n<p><strong>Renal Na+ absorption and water retention -&gt; due to increase aldosterone production via the renin angiotensin system as</strong> <strong>a consequence of placental estrogen production.</strong></p>\r\n<p><strong>ADH level remains unchanged throughout pregnancy.</strong></p>",
      "correct_choice_id": 134,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Arrhenoblastoma</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Thecoma</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Brenner tumour</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Carcinoid</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Virilising ovarian tumour is?</span></p>",
      "unique_key": "DT1322057",
      "question_audio": null,
      "question_video": null,
      "map_id": 1322057,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>Brenner and Carcinoid do not produce sex hormones(Option C,D ruled out)</li>\r\n<li>Thecoma is a sex hormone producing tumour but it secretes Estrogen(Option B ruled out)</li>\r\n<li><strong>Arrhenoblastoma(old terminology for Sertoli Leydig cell tumour) produces Androgens and causes virilization</strong>.</li>\r\n</ul>\r\n<p>Classification of ovarian tumours:</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGMCQ/202504074f46badf-6484-4b8a-af01-825a55887c94.jpg\">",
      "correct_choice_id": 141,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Decrease the dose of lithium</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">Increase the dose of lithium</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">Replace lithium with sodium valproate</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">Stop taking lithium altogether</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A pregnant female presented to OPD in 3rd trimester. She is known case of bipolar disorder with history of 3-4 exacerbation episodes. She's maintained well on lithium from last year. What is next appropriate management?</span></p>",
      "unique_key": "DT1322058",
      "question_audio": null,
      "question_video": null,
      "map_id": 1322058,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Fetal exposure to lithium causes: </strong>fetal and neonatal cardiac arrhythmia, hypoglycemia, nephrogenic diabetes insipidus, polyhydramnios, reversible changes in thyroid function, premature delivery, floppy infant syndrome.</p>\r\n<p>Small increase in congenital cardiac malformation (ebstein's anomaly).</p>\r\n<p><u>Physiological alteration in pregnancy may affect absorption, distribution, metabolism, and elimination of lithium.</u></p>\r\n<p>Women with bipolar disorder who are treated with lithium and plan to conceive:</p>\r\n<ul>\r\n<li>Mild and frequent episodes: treatment with lithium should be gradually tapered</li>\r\n<li>More severe episodes with moderate risk of relapse: taper dose of lithium and again reinstituted after organogenesis</li>\r\n<li>Severe and frequent episodes: continue same dose throughout pregnancy</li>\r\n<li>Fetal assessment with fetal echo considered in female who exposed with lithium in first trimester.</li>\r\n</ul>",
      "correct_choice_id": 151,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}